Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Cash from Operations (2018 - 2025)

10x Genomics' Cash from Operations history spans 8 years, with the latest figure at 40777000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations rose 704.28% year-over-year to 40777000.0; the TTM value through Dec 2025 reached 136050000.0, up 1941.57%, while the annual FY2025 figure was 136050000.0, 1941.57% up from the prior year.
  • Cash from Operations for Q4 2025 was 40777000.0 at 10x Genomics, down from 43214000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 43214000.0 in Q3 2025 and bottomed at 26216000.0 in Q3 2021.
  • The 5-year median for Cash from Operations is 481000.0 (2021), against an average of 3626900.0.
  • The largest annual shift saw Cash from Operations tumbled 643.69% in 2022 before it skyrocketed 704.28% in 2025.
  • A 5-year view of Cash from Operations shows it stood at 5805000.0 in 2021, then soared by 136.4% to 13723000.0 in 2022, then soared by 87.7% to 25758000.0 in 2023, then crashed by 126.2% to 6748000.0 in 2024, then surged by 704.28% to 40777000.0 in 2025.
  • Per Business Quant, the three most recent readings for TXG's Cash from Operations are 40777000.0 (Q4 2025), 43214000.0 (Q3 2025), and 17708000.0 (Q2 2025).